Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 31700262 | HLA-DQB1 (HLA-DQB1) | cramp | Korean | NA | NA | unclassified | |
| furthermore, we validated the potential molecular targets of the functions, representatively lcn2, cramp, and hla-dqb1, by western blotting.conclusionthese results may provide molecular signature candidates to elucidate the mechanisms of the immune response by krg. | |||||||
| 31718599 | HLA-DR (HLA-DR) | hypospadias | NA | NA | NA | unclassified | |
| langerhans cells in hypospadias: an analysis of langerin (cd207) and hla-dr on epidermal sheets and full thickness skin sections. | |||||||
| 31801816 | HLA (HLA) | plasmodium infection | NA | NA | NA | negation | |
| diverse populations of t cells that are not restricted to classical hla (unconventional t cells) participate in the host response during plasmodium infection. | |||||||
| 31826574 | NA (NA) | neuromyelitis optica spectrum disorders | NA | NA | NA | unclassified | |
| [expression of hla-dp in patients with neuromyelitis optica spectrum disorders]. | |||||||
| 31826574 | NA (NA) | neuromyelitis optica spectrum disorders | NA | NA | NA | unclassified | |
| objective: to investigate the effect of hla-dp gene expression on the susceptibility and disease status of neuromyelitis optica spectrum disorders (nmosd). | |||||||
| 31986138 | HLA (HLA) | anisakiasis | Croatian | NA | NA | only_studied | |
| genetic susceptibility to anisakiasis was evaluated by genotypisation of human leukocytes alleles (hla). | |||||||
| 32020202 | HLA-F (HLA-F) | rs2523405 | NA | rs2523393 | rs1362126 | positive+negation | |
| NA | |||||||
| 32183158 | HLA-B*27 | sulfasalazine | NA | hydroxychloroquine | NA | unclassified | |
| NA | |||||||
| 32709712 | HLA-DR (HLA-DR) | sting | NA | NA | NA | positive | |
| increased expressions of immunocompetence marker hla-dr (human leukocyte antigen dr antigen) on monocytes and of tbk1, a marker of sting (stimulator of interferon genes) pathway activation, in biopsies were associated with improved progression-free survival (pfs) (9.25 vs 3.5 months, p=0.019; 9 vs 3 months, p=0.003, respectively). | |||||||
| 34076478 | HLA-B*52 | sting | NA | NA | NA | only_studied | |
| we here investigated the priming with sting ligand of cd8+ t-cells specific for hla-b*52:01 or hla-c*12:02-restricted protective epitopes from naive t-cells. | |||||||
Copyright 2024